+44 20 8123 2220
info@marketpublishers.com

Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2022

https://marketpublishers.com/r/N565A9F869CEN.html
Date: January 2022
Pages: 90
Price: US$ 1,500.00 (Single User License)
ID: N565A9F869CEN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Spleen Tyrosine Kinase (SYK) Inhibitors- Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Spleen Tyrosine Kinase (SYK) Inhibitors Understanding

Spleen Tyrosine Kinase (SYK): Overview

SYK is a 72 kDa non-receptor tyrosine kinase, which contains two SRC homology 2 (SH2)-domains and a kinase domain, and is most highly expressed by haematopoietic cells. Mammals also express a SYK homologue, ZAP70, which is mostly restricted to T- and NK-lineage cells. SYK-related kinases are also found in invertebrates.

Structure and Signaling of the SYK Receptor

SYK contains two tandem SH2 domains and a C-terminal tyrosine kinase domain.

+44 20 8123 2220
info@marketpublishers.com

These domains are linked by two linker regions: interdomain A between the two SH2 domains and interdomain B between the C-terminal SH2 domain and the kinase domain. An alternatively spliced form of SYK (known as SYK-B) lacks 23 amino acids of interdomain B, including a nuclear localization signal.

The SYK signalling pathway was initially thought to be restricted to classical immunoreceptors of the adaptive immune response. However, later studies showing that glycoprotein VI (GpVI), a collagen-receptor expressed by platelets, also signals by a similar mechanism2, and that thepetechiated appearance of SYK-deficient embryos was due to a defect in lymphatic vascular development3 provided evidence for the role of SYK outside the adaptive immune response.

Expression

SYK is highly expressed by all haematopoietic lineage cells. Though the expression of SYK is tightly regulated the mechanism of this regulation, or that of the generation of the SYK-B isoform, is poorly understood. Mammals also express the SYK-related molecule ZAP70, the expression of which is mostly confined to the T and NK cell lineages.

Spleen Tyrosine Kinase (SYK) Inhibitors

While SYK inhibitors have shown positive effects in allergy, autoimmune diseases and B-lineage malignancies, the mechanism of their action is incompletely understood. This is in part due to the diverse roles of SYK in immunological functions. As an example, B-cell-mediated antigen presentation and autoantibody formation, Fc-receptor-mediated myeloid cell functions and ?2 integrin-mediated leukocyte activation have all been implicated in the pathogenesis of rheumatoid arthritis and they all have been shown to require SYK.

Spleen Tyrosine Kinase (SYK) Inhibitors Emerging Drugs Chapters

This segment of the Spleen Tyrosine Kinase (SYK) Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Spleen Tyrosine Kinase (SYK) Inhibitors Emerging Drugs

+44 20 8123 2220
info@marketpublishers.com

Cevidoplenib dimesylate: Genosco

The dimesylate salt of cevidoplenib, an orally available inhibitor of spleen tyrosine kinase (SYK), with potential anti-inflammatory and immunomodulating activities. Upon oral administration, cevidoplenib binds to and inhibits the activity of SYK, blocking Fc receptor and B-cell receptor (BCR)-mediated signaling in inflammatory cells, including macrophages, neutrophils, mast cells, natural killer (NK) cells and B cells. This leads to the inhibition of the activation of these inflammatory cells, and the related inflammatory responses and tissue damage.

HMPL-523: Hutchison MediPharma

An orally available inhibitor of spleen tyrosine kinase (Syk), with potential immune-modulating and antineoplastic activities. Upon oral administration of Syk inhibitor HMPL-523, this agent binds to and inhibits the activity of Syk. This inhibits B-cell receptor (BCR) signaling, which leads to the inhibition of B-cell activation, and prevents tumor cell activation, migration, adhesion and proliferation.

Further product details are provided in the report……..

Spleen Tyrosine Kinase (SYK) Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Spleen Tyrosine Kinase (SYK) Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Spleen Tyrosine Kinase (SYK) Inhibitors

There are approx. 10+ key companies which are developing the therapies for Spleen Tyrosine Kinase (SYK) Inhibitors. The companies which have their Spleen Tyrosine Kinase (SYK) Inhibitors drug candidates in the most advanced stage, i.e. phase II and Phase II/III include, Rigel Pharmaceuticals, TopiVert etc.

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical

+44 20 8123 2220
info@marketpublishers.com

development like

Late-stage products (Phase II and Phase II/III)

Mid-stage products (Phase II and Phase II/III)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Spleen Tyrosine Kinase (SYK) Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal antibodies

Small molecules

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Spleen Tyrosine Kinase (SYK) Inhibitors: Pipeline Development Activities

+44 20 8123 2220
info@marketpublishers.com

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spleen Tyrosine Kinase (SYK) Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spleen Tyrosine Kinase (SYK) Inhibitors drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Spleen Tyrosine Kinase (SYK) Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Spleen Tyrosine Kinase (SYK) Inhibitors.

August 2020: SKI-O-703 (SYK inhibitor) is currently undergoing two Phase 2 clinical trials in rheumatoid arthritis (RA) and idiopathic thrombocytopenic purpura (ITP).

Spleen Tyrosine Kinase (SYK) Inhibitors Report Insights

Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Spleen Tyrosine Kinase (SYK) Inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

+44 20 8123 2220
info@marketpublishers.com

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Spleen Tyrosine Kinase (SYK) Inhibitors drugs?

How many Spleen Tyrosine Kinase (SYK) Inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Spleen Tyrosine Kinase (SYK) Inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Spleen Tyrosine Kinase (SYK) Inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Spleen Tyrosine Kinase (SYK) Inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Genosco

Portola Pharmaceuticals

+44 20 8123 2220
info@marketpublishers.com

GlaxoSmithKline

FUJIFILM Corporation

TopiVert

Takeda Oncology

Asana BioSciences

Key Products

CVXL-0074

Cevidoplenib

PRT 2761

GSK 2646264

Cevidoplenib

FF 10102 01

TOP 1630

Mivavotinib

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Spleen Tyrosine Kinase (SYK) Inhibitors - Pipeline Insight, 2022
Product link: https://marketpublishers.com/r/N565A9F869CEN.html
Price: US$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/N565A9F869CEN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970